Introduce 'Grow Your Own' Laws for Legal Medical Cannabis Patients (CBPM)
- 575 Signatures
(Estimated Final Signatures: 6,470 - 217 added in the past 24hrs)
We think patients prescribed 'CBPM' by a medical specialist should be allowed to maintain 3-6 flowering plants (with extra considerations for starting new seedlings).
Found: There are 45,000 legal medical cannabis patients across the UK, prescribed primarily bud/flower or refined
Asked by: Sarah Dyke (Liberal Democrat - Glastonbury and Somerton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress she has made with (a) regulatory, (b) research and (c) NHS partners on establishing clinical trials to test the (i) safety and (ii) efficacy of medical cannabis products.
Answered by Andrew Stephenson
The Department, via the National Institute for Health and Care Research (NIHR), is developing a programme of two randomised controlled trials to test the safety and efficacy of medicinal cannabis products to treat epilepsy in adults and children. The trials will start as soon as possible, and the results will be published once the trials have completed and the findings peer reviewed.
Furthermore, the Government continues to encourage manufacturers to invest in research and has highlighted that public funding is available for high quality applications. The Medicines and Healthcare products Regulatory Agency and the NIHR can provide applicants with scientific and research advice.
Mentions:
1: McNair, Marie (SNP - Clydebank and Milngavie) group, I was interested to learn from its members about the possible positive benefits of medicinal cannabis - Speech Link
2: White, Tess (Con - North East Scotland) As co-convener of the CPG on medicinal cannabis, I have heard some really difficult stories of parents - Speech Link
Asked by: Sarah Dyke (Liberal Democrat - Glastonbury and Somerton)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment she has made of the potential merits of allowing children to be issued medical cannabis prescriptions on the NHS.
Answered by Andrew Stephenson
Licensed cannabis-based medicines, that have been proved effective in clinical trials and judged cost-effective by the National Institute of Health and Care Excellence (NICE), are routinely available on the National Health Service, including for people aged over two years old with certain types of epilepsy. However, clinical guidelines from NICE demonstrate a clear need for more evidence to support routine prescribing and funding decisions for unlicensed cannabis-based medicines.
We continue to call on manufacturers to conduct research to prove if their products are safe and effective and we are working with regulatory, research and NHS partners to establish clinical trials to test the safety and efficacy of these products.
Apr. 09 2024
Source Page: Reform to the fees applicable under the hemp licensing regimeFound: Cannabis is defined in section 37(1) of the 1971 Act.
Apr. 09 2024
Source Page: Reform to the fees applicable under the hemp licensing regimeFound: Cannabis is defined in section 37(1) of the 1971 Act.
Asked by: Greer, Ross (Scottish Green Party - West Scotland)
Question
To ask the Scottish Government whether it will provide an update on what its position is on the addition of medicinal cannabis to NHS Scotland formularies.
Answered by Minto, Jenni - Minister for Public Health and Women's Health
There are three licensed Cannabis Based Products for Medicinal use (CBPMs) available on the NHS in Scotland to treat specific conditions. These are:
The decision on whether to make a licensed medicine routinely available on the NHS in Scotland is made by healthcare professionals and other experts who make up the Scottish Medicines Consortium (SMC), following an application by the manufacturer. This is independent of Scottish Ministers. If a medicine is recommended for use,- Health Boards’ local Area Drug and Therapeutic Committees will consider and decide whether to include it in their prescribing formulary.
Clinical guidance does not recommend the prescribing of unlicensed CBPMs, other than in clinical trials. The biggest barrier to the prescribing of other CBPMs on the NHS is that most products remain unlicensed with a limited, or non-existent, peer-reviewed clinical evidence base for their use.
Apr. 09 2024
Source Page: Hemp licensing changes will help grow UK economyFound: Hemp is a variety of cannabis containing less than 0.2% THC.
Asked by: Andrew Rosindell (Conservative - Romford)
Question to the Department for Business and Trade:
To ask the Secretary of State of Business and Trade, what estimate she has made of the contribution of domestic medicinal cannabis production to the economy.
Answered by Kevin Hollinrake - Shadow Secretary of State for Levelling Up, Housing and Communities
The Department for Business and Trade (DBT) actively assists life sciences companies in their endeavours to invest, expand, and export, thereby generating employment and economic growth.
UK-based life sciences businesses receive support from DBT through trade missions to key markets, participation in major trade events, tackling market access barriers, upskilling exporters, and guidance on entering new markets. Although routine assessments of the economic impact of specific life sciences’ subsectors like medicinal cannabis are not conducted, DBT is committed to supporting companies of various sizes throughout their export and inward investment endeavours while adhering to national regulatory guidelines.
Written Evidence May. 14 2024
Inquiry: Modern Slavery Act 2015Found: foreign nationals who received custodial sentences after being found guilty of the production of cannabis